Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.
We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia. This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss. Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described. Careful use of epsilon-aminocaproic acid therapy is recommended.
Achiron
A
A
Department of Neurology, Beilinson Medical Center, Petach-Tiqva, Israel.
Gornish
M
M
Melamed
E
E
D000328:Adult; D000614:Aminocaproates / Q000009:adverse effects*; D015119:Aminocaproic Acid / Q000009:adverse effects*; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008595:Menorrhagia / Q000188:drug therapy*; D012851:Sinus Thrombosis, Intracranial / Q000139:chemically induced* / Q000175:diagnosis
D000614:Aminocaproates; D005343:Fibrinolytic Agents; D015119:Aminocaproic Acid